🇺🇸 FDA
Patent

US 10287297

Epoxyazulene derivatives useful for treating cancer and diabetes

granted A61PA61P3/10A61P35/02

Quick answer

US patent 10287297 (Epoxyazulene derivatives useful for treating cancer and diabetes) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P3/10, A61P35/02